Pharmafile Logo
Pharmafocus logo
Advanced Search

morphosys

Showing 12 posts of 12 posts found.

Novartis to acquire MorphoSys AG for €2.7bn

February 6, 2024
Business Services Novartis, Pharmacy, acquisition, morphosys

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, or €68 per share. The …

News

MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment

November 23, 2023
Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib

MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …

News
fdaoutsideweb

FDA gives nod for Monjuvi combo for second-line relapsed or refractory diffuse large B-cell lymphoma

August 3, 2020
Sales and Marketing FDA, Incyte, Monjuvi, morphosys, pharma

The FDA has awarded MorphoSys and Incyte US approval for their Fc-modified cytolytic CD19-targeting monoclonal antibody Monjuvi (tafasitamab-cxix), when used …

News
shutterstock_512649

MorphoSys and Incyte forge potential $1.1bn partnership to develop B cell malignancy drug candidate

January 14, 2020
Manufacturing and Production, Sales and Marketing Incyte, morphosys, pharma, tafasitamab

MorphoSys and Incyte have joined together in a partnership to develop and commercialise the latter’s anti-CD19 antibody tafasitamab as a …

News
jp-kress_mor

Working Life Interview: Jean-Paul Kress, CEO of MorphoSys

January 13, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Working Life, feature, morphosys, pharma

With a medical doctorate as well as degrees in pharmacology and immunology under your belt, was your path always to …

Feature
shutterstock_212432119

Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate

October 31, 2019
Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma

The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …

News
lab

Novartis muscular drug fails in Phase III trials

April 22, 2016
Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …

News
legal

Janssen and Genmab sued for patent infringement in US

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement

German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).

News
Red blood cells

ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data

December 8, 2015
Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology

Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …

News
GSK image

GSK licences RA drug

June 5, 2013
Research and Development, Sales and Marketing GSK, RA, morphosys

GlaxoSmithKline is gambling millions of euros on an investigational drug in a bid to get an edge in the fight …

News

Pharma manufacturing news in brief

March 22, 2011
Manufacturing and Production American Regent, Berkshire Hathaway, Cytovance, Intercell, Solagran, West Pharmaceutical Services, morphosys, pharma contract manufacturing

Lubrizol bought for $9.7 billion by Berkshire Hathaway, plus the latest pharma manufacturing and quality news. Berkshire Hathaway, run by …

News
LisaRojkjaer100

Dr Lisa Rojkjaer, head of clinical development, MorphoSys

October 15, 2009
Research and Development appointment, morphosys, research and development

MorphoSys has appointed Dr Lisa Rojkjaer as vice president and head of clinical development. Dr Rojkjaer joins MorphoSys from Novartis …

Appointment

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024